Stereoselective Rearrangements for the Synthesis of Bioactive Small Molecules

用于合成生物活性小分子的立体选择性重排

• 批准号: 9066717
• 负责人: UTTAM Krishan TAMBAR
• 金额: $ 31.01万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9066717
• 关键词: Alkenes; Amination; Amines; Amino Acids; Amino Alcohols; Ammonium; Antineoplastic Agents; Area; Belief; Biological; Cancer cell line; Carbohydrates; Catalysis; Chemicals; Chemistry; Collaborations; Complex; Development; Disease; Drug Targeting; Glycobiology; Goals; Growth; Health; Human; Libraries; Ligands; Malignant Neoplasms; Marketing; Medical center; Medicine; Metabolic; Metals; Methods; Monosaccharides; Natural Products; Nitrogen; PDH kinase; Palladium; Pharmaceutical Preparations; Pharmacologic Substance; Play; Process; Reaction; Research; Role; Structure; Therapeutic; Transition Elements; analog; base; biological systems; chemical reaction; cytotoxic; innovation; interest; novel; novel strategies; programs; small molecule; small molecule inhibitor; tertiary amine; tool; tumor; ylide

DESCRIPTION (provided by applicant): Stereoselective chemical reactions have transformed the practice of human medicine by providing access to chemical tools to study biological systems and pharmaceutical drugs to treat disease. Although several methods exist for the synthesis of biologically valuable chiral compounds, there is great potential for discovering conceptually novel strategies in catalysis for the stereoselective synthesis of classes of medicinally relevant molecules that are not easily synthesized by known methods. In particular, there are many synthetically useful rearrangements that are underdeveloped in the realm of asymmetric metal catalysis. The long- term goals for this research program include the discovery of general strategies for the catalytic conversion of simple starting materials into structurally complex and biologically active small molecules. These new methods will challenge established opinions on the chemistry of reactive zwitterions and tertiary amines as substrates for metal-catalyzed rearrangement processes. In addition to developing innovative chemical strategies, the proposed research program will explore unique opportunities for biomedical collaborations with cancer biologists at UT Southwestern Medical Center. The research strategy is divided into two project areas: A. Enantioselective [2,3]-Rearrangements of Reactive Zwitterions: Project A is guided by the innovative hypothesis that reactive zwitterionic intermediates can be subjected to metal- catalyzed enantioselective [2,3]-rearrangements, despite their propensity to undergo facile thermal sigmatropic rearrangements. Specific Aim A.1: Metal-Catalyzed Enantioselective Allylic Amination Specific Aim A.1: Stereoselective Synthesis of Amino alcohols and Selectively Protected Monosaccharides B. Tandem Allylic Amination / Rearrangement Reactions with Tertiary Amines: Project B is guided by the innovative hypothesis that tertiary amines can serve as general nucleophiles for metal-catalyzed allylic aminations in the context of stereoselective tandem processes, despite the long-held belief that these substrates are not general nucleophiles in metal catalysis. Specific Aim B.1: Development of an Enantioselective [2,3]-Stevens Rearrangement Specific Aim B.2: Stereoselective Synthesis of Small Molecule Inhibitors of PDK 2 (cancer drug target) - Collaboration with David Chuang

描述（由申请人提供）：立体选择化学反应通过提供化学工具来研究生物系统和治疗疾病的药物，已经改变了人类医学的实践。虽然有几种方法可用于合成具有生物学价值的手性化合物，但在发现概念上新颖的策略以催化立体选择性合成类别的药物相关分子方面具有很大的潜力，这些分子不易用已知方法合成。特别是，在不对称金属催化领域中，有许多合成上有用的重排尚未开发。该研究计划的长期目标包括发现将简单起始材料催化转化为结构复杂且具有生物活性的小分子的一般策略。这些新方法将挑战关于反应性两性离子和叔胺作为金属催化重排过程底物的化学观点。除了开发创新的化学策略外，拟议的研究项目还将探索与德克萨斯大学西南医学中心的癌症生物学家进行生物医学合作的独特机会。研究策略分为两个项目领域：A.对映选择性[2,3]-反应性两性离子重排：项目A以创新假设为指导，即反应性两性离子中间体可以进行金属催化的对映选择性[2,3]重排，尽管它们倾向于进行容易的热异位重排。特异性目的A.1：金属催化对映选择性烯丙基胺化；特异性目的A.1：立体选择性合成氨基醇和选择性保护单糖；项目B是由一个创新的假设指导的，即叔胺可以作为金属催化的烯丙基胺在立体选择的背景下的一般亲核试剂，尽管长期以来认为这些底物在金属催化中不是一般的亲核试剂。特异性Aim B.1：对映选择性[2,3]- stevens重排特异性Aim B.2：立体选择性合成pdk2小分子抑制剂（癌症药物靶点）-与David Chuang合作